Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET

Company Participants

Richard Francis - President & CEO

Eli Kalif - CFO

Dr. Eric Hughes - CMO, Head of R&D

Sven Dethlefs - Head, North America Commercial

Ran Meir - IR

Conference Call Participants

Jason Gerberry - Bank of America

Umer Raffat - Evercore ISI

Mikaela Franceschina - Barclays

Ash Verma - UBS

Thibault Boutherin - Morgan Stanley

David Amsellem - Piper Sandler

Chris Schott - J.P. Morgan

Operator

Hello, and welcome to the Q2 2023 Teva Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex. I'll be coordinating the call today. [Operator instructions].

I'll now hand over to your host, Ran Meir, head of Investor Relations. Please go ahead.

Ran Meir

Thank you, Alex. Thank you, everyone, for joining us today. We hope you have had an opportunity to review our press release, which was issued earlier this morning. A copy of this press release, as well as a copy of the slides being presented on this call, can be found on our website at tevapharm.com.

Please review our forward-looking statement on Slide No. 2. Additional information regarding these statements and our non-GAAP financial measures is available on our earning release and in our SEC Forms 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q2 2023 results and business performance, as well as recent events, and our priorities going forward. Then Dr. Eric Hughes, our head of R&D and Chief Medical Officer, will discuss progress on our innovative pipeline. Our CFO, Eli Kalif, will follow up by reviewing the financial results in more details, including our 2023 financial outlook. Joining Richard, Eric, and Eli on the call today is Sven Dethlefs, Teva's head of North America business, who will be available during the question-and-answer session that will follow the presentation. Please note that today's call will run approximately one hour.

And with that, I will now turn the call over to Richard. Richard, if you would, please?

Richard Francis

Thank you, Ran, and thank you, everybody, for joining our call. I'm very pleased to update you on our Q2 performance and the progress we are making on executing our Pivot to Growth strategy. It's been an exciting quarter, with the launch of AUSTEDO XR, our once-a-day formulation, and the launch of UZEDY, our long-acting treatment for schizophrenia.